Japanese firms link up to develop HCC (hepatocellular carcinoma) test kit:
This article was originally published in Clinica
Three Tokyo firms - Sanko Junyaku, Eisai and Fujirebio - have signed a joint research agreement to develop a test kit for hepatocellular carcinoma (HCC), the fourth leading cause of malignant-tumour related death in Japan. The kit will test for DCP (des-gamma-carboxy prothrombin), a marker for HCC. It will be used exclusively with Fujirebio's Lumipulse chemiluminescent enzyme immunoassay system. Fujirebio will manufacture the product for distribution by Sanko Junyaku and sales partner Eisai.
You may also be interested in...
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.
Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.
Market researcher The NPD Group identifies the few prestige beauty categories that posted sales growth in the US for the week ending 28 March. Companies that can pivot or ramp up activities in winning segments – and reach consumers digitally while they shelter at home – may fare best during the coronavirus pandemic.